drugset / Trial / NCT03178643

Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)

NCT03178643

RandomizedParallel-groupOpen-labelPrevention

Summary

This is a randomized, three-arm, open-label, clinical trial of malaria chemoprevention in children with sickle-cell anemia (SCA) at a single site in Homa Bay, Kenya. The study will enroll 246 children under 10 years of age, randomize participants 1:1:1 to one of three malaria chemoprevention regimens, and follow participants monthly for 12 months in order to record clinical episodes of malaria or SCA-related morbidity. Analyses will compare the efficacy of each regimen to prevent malaria and SCA morbidity.

Timeline

Start
2018-01-23
Primary completion
2020-12-16
Completion
2020-12-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 10 mg
Comparator ARTENIMOL Small molecule 20 mg
Comparator ARTENIMOL Small molecule 30 mg
Comparator ARTENIMOL Small molecule 40 mg
Comparator ARTENIMOL Small molecule 50 mg
Comparator ARTENIMOL Small molecule 60 mg
Comparator Proguanil Small molecule 3 mg/kg Oral
Comparator amodiaquine Other / unclassified 153 mg
Comparator amodiaquine Other / unclassified 229.5 mg
Comparator piperaquine Small molecule 80 mg
Comparator piperaquine Small molecule 160 mg
Comparator piperaquine Small molecule 240 mg
Comparator piperaquine Small molecule 320 mg
Comparator piperaquine Small molecule 400 mg
Comparator piperaquine Small molecule 480 mg
Comparator pyrimethamine Small molecule 25 mg
Comparator pyrimethamine Small molecule 37.5 mg
Comparator sulfadoxine Small molecule 500 mg
Comparator sulfadoxine Small molecule 750 mg